Navigation Links
Poniard Pharmaceuticals Announces $6.3 Million Financing
Date:3/15/2010

h the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

SOURCE Poniard Pharmaceuticals, Inc.

Back to top

RELATED LINKS
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
2. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
3. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
4. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
5. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
6. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
7. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
9. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
10. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... with the prior year. Reported sales decreased 4% as ... , Net earnings per diluted share as reported ... period. Adjusted EPS was $2.80 , an increase ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... , , , , ... this month, dog owners in the Midwest will find that getting their ... the Mobile Dog Heart Health Tour will make stops with a sound-proof ... in Chicago on August 30 to perform free dog heart examinations. , ...
... REHOVOT, Israel, August 17 D-Pharm ... 85 million (approximately,$23M USD) to fund the Company,s late stage ... NIS 57 million and an Initial,Public Offering (IPO) of NIS ... set at 133 NIS, 13% higher than the minimum price. ...
Cached Medicine Technology:Midwest Mobile Dog Heart Health Tour to Provide Free Heart Examinations 2Midwest Mobile Dog Heart Health Tour to Provide Free Heart Examinations 3D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE) 2D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE) 3
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the STASH ... STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured ... tried-and-true products that have stood the test of time. These include lighting products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and ... new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for ... commemorate introduction of this new type of sod, Super-Sod is giving away red Adirondack ...
(Date:7/31/2015)... ... 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, ... is the Super Bowl. In the two weeks that separate the conference championships and the ... 2016 Super Bowl game will mark the 50th time it has been held and the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... Claremont Lawyer Calls upon State Regulators to Impose ... Suspend Insurer,s License for Lying to State Investigators, ... litigator,William Shernoff yesterday filed a class action lawsuit ... insurer,s unlawful practice of,retroactively canceling health insurance policies ...
... Myers, Inc.,(NYSE: RBN ) announced today that it ... Capital Goods Conference in New York City on,November 28, ... Christopher M. Hix, Vice President and Chief Financial Officer, ... is set for 2:00-2:25 p.m., EST, on,Wednesday, November 28th ...
... sites nationwide , FRIDAY, Nov. 16 (HealthDay News) ... and environmental factors that may cause autism, as well ... and their families from six areas in the United ... which researchers called the largest of its kind -- ...
... Holes Between Ribs ... 1/2 Days, TYLER, Texas, Nov. 16 62-year-old Canton ... first in east,Texas to benefit from a heart bypass procedure ... Roden was released from the,hospital just 1 1/2 days after ...
... Md., Nov. 16 According to the,recently ... Study on,Attention-Deficit/Hyperactivity Disorder (MTA) in the August ... of Child and Adolescent Psychiatry,(JAACAP), children and ... medication alone or in combination with behavioral ...
... (OTC Bulletin Board: VQPH), a New Jersey-based,biopharmaceutical company ... for the three and nine months ended,September 30, ... operations,for the three months ended September 30, 2007, ... a loss of $911,125, or $0.02 per share, ...
Cached Medicine News:Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 3Health News:Major U.S. Autism Study Gets Under Way 2Health News:Video: Patient at Mother Frances Receives Heart Bypass Without Opening Chest 2Health News:VioQuest Pharmaceuticals Announces Third Quarter and Nine Months 2007 Results 2Health News:VioQuest Pharmaceuticals Announces Third Quarter and Nine Months 2007 Results 3Health News:VioQuest Pharmaceuticals Announces Third Quarter and Nine Months 2007 Results 4Health News:VioQuest Pharmaceuticals Announces Third Quarter and Nine Months 2007 Results 5Health News:VioQuest Pharmaceuticals Announces Third Quarter and Nine Months 2007 Results 6Health News:VioQuest Pharmaceuticals Announces Third Quarter and Nine Months 2007 Results 7
... color monitor produces superb ... icons for easier identification ... choices for measurement. Allows ... smaller pupils than conventional ...
Auto refractometer....
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
... most advanced automatic refractor/keratometer ... today. It adds the ... readings simultaneously. It also ... focusing, automatic tracking, automatic ...
Medicine Products: